These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36749444)

  • 21. Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas.
    Schebesch KM; Brawanski A; Doenitz C; Rosengarth K; Proescholdt M; Riemenschneider MJ; Grosse J; Hellwig D; Höhne J
    Clin Neurol Neurosurg; 2018 Sep; 172():177-182. PubMed ID: 30032095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
    Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
    J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
    Berger TR; Wen PY; Lang-Orsini M; Chukwueke UN
    JAMA Oncol; 2022 Oct; 8(10):1493-1501. PubMed ID: 36006639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
    Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiographic growth rate as a predictor of aggressiveness of diffuse gliomas without 1p19q codeletion.
    Leclerc A; Roux A; Elia A; Peeters S; Aboubakr O; Bedioui A; Planet M; Benzakoun J; Simboli GA; Tauziede-Espariat A; Moiraghi A; Varlet P; Chrétien F; Oppenheim C; Zanello M; Pallud J
    Neurosurg Focus; 2024 Feb; 56(2):E4. PubMed ID: 38301236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
    Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
    Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
    Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
    Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.
    Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Martinez-Zalacain I; Castell J; Camins A; Vidal N; Bruna J; Cos M; Perez-Lopez R; Oleaga L; Warnert E; Smits M; Majos C
    Eur Radiol; 2024 Aug; 34(8):5320-5330. PubMed ID: 38282078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.
    Noble Anbunesan S; Alfonso-Garcia A; Zhou X; Bec J; Lee HS; Jin LW; Bloch O; Marcu L
    J Biophotonics; 2023 Apr; 16(4):e202200291. PubMed ID: 36510639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.